Skip to main
ABEO
ABEO logo

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics Inc is projected to achieve approximately $32 million in top-line revenue for 2025, with an anticipated increase to $130.4 million in 2026, indicating robust growth potential. The favorable market access situation is expected to improve over the coming months, which could further enhance revenue forecasts. Additionally, the company's pipeline assets, including gene therapies for rare genetic diseases, are positioned to drive significant upside, reinforcing a positive outlook on its financial trajectory.

Bears say

Abeona Therapeutics faces several significant risks that contribute to a negative outlook on its stock. The potential for slower than projected market uptake of its key product, pz-cel, in the United States raises concerns about revenue generation, while challenges in optimizing the product's value in international markets add further uncertainty. Additionally, setbacks in the company's earlier-stage pipeline programs and the risk of long-term dilution could negatively impact investor confidence and financial stability.

Abeona Therapeutics (ABEO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Abeona Therapeutics (ABEO) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.